Short Path to the Truth

Straightforward Questions to Industry Executives and Insiders 

• To Pharma:
  • How much are you paying health insurer/PBMs?
  • How are you paying them?
    • Rebates vs. Fees vs. other ways?
    • Are the “pharma fees” tied to brand drug “sticker” prices?
  • What are you paying them these “pharma fees” for?
    • What “support services” are the PBMs providing for these fees?
    • How was the “fair” payment determined for these “services”, as is required by law? 

• To Health Insurer/PBMs:
  • How much of your brand drug revenues/profits come from pharma?
    • From “rebates” vs. “pharma fees”?
  • How are these “pharma fees” paid?
    • Percent contracts tied to brand “sticker” prices?
    • What are you getting these “pharma fees” for?
      • What “support” work?
      • How is it a “fair” price?
    • In Part D, have these “pharma fees” been reported to the Government?
      • How much reported?
      • Where reported? 

Readily Accessible Investigative Data 

• • National pharma/PBM “fee” contracts
  • National Medicare Part D data
  • Detailed Part D documentation requirements
  • Clear Part D “pharma fee” legal requirements 

Nothing subtle regarding the extreme taxpayer harm and alleged "kickbacks" in these vast Whistleblower cases

• • 8-to-10-fold price increases
  • Vast increases in U.S. Pharma brand sales driven ONLY by these massive price increases, as use by physicians and patients has sharply declined
  • Massive “pharma fees” paid to health insurers/PBMs for doing a lot less legitimate work
  • Massive and unprecedented Whistleblower alleged taxpayer harm
    • In excess of $175 billion over the past decade-plus and ongoing
    • The largest alleged healthcare Whistleblower case in U.S. history, by a wide margin
  •  Severe and escalating patient, family, business and taxpayer harm across the nation

• DOJ ADMITTED NOT DIRECTLY PURSUING THE CENTRAL KICKBACK AND OTHER KEY ALLEGATIONS IN ITS INVESTIGATION OF THESE WHISTLEBLOWER CASES 

• Link to my Court affidavit regarding DOJ’s admitted Whistleblower case investigative failures